What is the current stock price of Omnicell, Inc. (OMCL)?

As of the latest market data, Omnicell, Inc. (OMCL) is trading at $38.28. The stock has seen a gain of 1.81% today.

Does Omnicell, Inc. (OMCL) pay a dividend?

Based on current data, Omnicell, Inc. does not have a confirmed active dividend policy.

What is the market cap of Omnicell, Inc.?

The current market capitalization of Omnicell, Inc. (OMCL) is approximately unavailable.

OMCL

Omnicell, Inc.·Healthcare

38.28

1.809%(+0.68)

Close Price

40.24

5.120%(+1.96)

Pre-Market

Last Updated: — ET

52W L: $22.6652W H: $55.00

OMCL NEWS

businesswire.com

6d ago

Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026.

defenseworld.net

Apr 6

Reviewing Omnicell (NASDAQ:OMCL) & Tivic Health Systems (NASDAQ:TIVC)

Tivic Health Systems (NASDAQ: TIVC - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Earnings and Valuation This table compares Tivic

zacks.com

Mar 24

Should You Continue to Hold OMCL Stock in Your Portfolio?

Omnicell's autonomous pharmacy push and SaaS growth show promise, but rising costs and weak hospital spending cloud its near-term outlook.

defenseworld.net

Mar 22

Financial Analysis: Omnicell (NASDAQ:OMCL) versus Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ: NYXH - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation. Volatility and Risk Nyxoah has a beta of 1.56,

defenseworld.net

Feb 27

Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Omnicell, Inc. (NASDAQ: OMCL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The

defenseworld.net

Feb 23

Hillsdale Investment Management Inc. Purchases 41,500 Shares of Omnicell, Inc. $OMCL

Hillsdale Investment Management Inc. boosted its position in Omnicell, Inc. (NASDAQ: OMCL) by 40.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 144,427 shares of the company's stock after acquiring an additional 41,500 shares during the period. Hillsdale Investment

Company Profile

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Employees

3,620

IPO Date

2001-08-09

Beta

0.86

Websitewww.omnicell.com↗